Bcl-2 expression in malignant melanoma and its prognostic significance.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Surgical Oncology

• Publication date

  1996-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0748-7983(96)90176-6PMID 8783649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• bcl‐2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic Nevi

  1995cited by this paper
• Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

  1995cited by this paper
• What is the value of bcl‐2 protein detection for histopathologists?

  1995cited by this paper
• The regulation of p53 function: Steiner award lecture

  1994cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.

  1993cited by this paper
• Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

  1993cited by this paper
• bcl-2 protein in non-small-cell lung carcinoma.

  1993cited by this paper
• The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction

  1990cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation.

  1990cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Cutaneous malignancies in chronic lymphocytic leukemia

  2024influential citation
• Therapeutics targeting BCL2 family proteins

  2022cites this paper
• Cellular demolition: Proteins as molecular players of programmed cell death.

  2019cites this paper
• Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.

  2018cites this paper
• Skin Cancers Associated with Lymphoid Malignancies

  2018cites this paper
• Expression of the uncharacterised isoform, BCL2β, in melanoma

  2017influential citation
• BCL2 Family, Mitochondrial Apoptosis, and Beyond

  2016cites this paper
• Thiosemicarbazones Target Multiple Resistance Pathways in Cancer

  2016influential citation
• Targeting Cell Survival Proteins for Cancer Cell Death

  2016cites this paper
• Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

  2015cites this paper
• TETHERED IL-15 TO AUGMENT THE THERAPEUTIC POTENTIAL OF T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR: MAINTAINING MEMORY POTENTIAL, PERSISTENCE, AND ANTITUMOR ACTIVITY

  2014cites this paper
• Defective Apoptosis Signaling in Cancer

  2013cites this paper
• Targeting the Bcl-2 family for cancer therapy

  2013cites this paper
• Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment

  2011cites this paper
• Assessment of prognostic markers in benign and malignant melanocytic tumours

  2011cites this paper
• Prognostic Significance of iNOS in Human Melanoma

  2010cites this paper
• Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours

  2010cites this paper
• Cytokines and Growth Factors Expressed by Human Cutaneous Melanoma

  2010cites this paper
• Metachronous Primary Melanoma and Lymphoma

  2010cites this paper
• Melanoma: targeting signaling pathways and RaLP

  2009cites this paper
• Melanoma: targeting signaling pathways and RaLP.

  2009cites this paper
• E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression.

  2009cites this paper
• Targeted therapy for uveal melanoma.

  2008cites this paper
• Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels.

  2008cites this paper
• bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: A historical cohort study

  2008cites this paper
• Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors

  2007cites this paper
• Modulating mitochondria-mediated apoptotic cell death through targeting of Bcl-2 family proteins.

  2007cites this paper
• Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease

  2007cites this paper
• IAPs as a target for anticancer therapy.

  2007cites this paper
• Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress

  2006cites this paper
• The Role of DCT/TYRP2 in Resistance of Melanoma Cells to Drugs and Radiation

  2006cites this paper
• Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.

  2005cites this paper
• Experimental therapy using interferon-gamma and anti-Fas antibody against oral malignant melanoma cells

  2005cites this paper
• Novel apoptosis inducing agents in cancer therapy.

  2005cites this paper
• Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence

  2005cites this paper
• Clinical studies of antisense oligonucleotides for cancer therapy.

  2005cites this paper
• Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.

  2005cites this paper
• Analysis of Bcl-2 protein expression in choroidal melanomas

  2005cites this paper
• Molecularly targeted agents: their promise as cancer chemopreventive interventions.

  2005cites this paper
• The Intrinsic (Mitochondrial) Death Pathway and New Cancer Therapeutics: Bcl-2 Family in Focus

  2005cites this paper
• Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma

  2005cites this paper
• Induction of Apoptosis by G3139 in Melanoma Cells

  2005cites this paper
• [Multidrug resistance in uveal melanoma].

  2005cites this paper
• Multichimiorésistance du mélanome uvéal

  2005cites this paper
• A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

  2004cites this paper
• CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression

  2004cites this paper
• Multidrug resistance in solid tumours

  2004cites this paper
• DNA repair pathways in drug resistance in melanoma

  2004cites this paper
• Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells

  2004cites this paper
• Lineage-specific Mechanism of Drug and Radiation Resistance in Melanoma Mediated by Tyrosinase-related Protein 2

  2004cites this paper
• c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers

  2004cites this paper
• The role of Bcl-2 family members in the progression of cutaneous melanoma

  2004cites this paper
• Systemic Treatment in Advanced Melanoma: Innovative Perspectives

  2003cites this paper
• Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy

  2003cites this paper
• Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

  2003cites this paper
• The future of antisense therapy: combination with anticancer treatments

  2003cites this paper
• Human melanoma: drug resistance.

  2003cites this paper
• Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2

  2003cites this paper
• Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family

  2003cites this paper
• Tumor regression by combination antisense therapy against Plk1 and Bcl-2

  2003cites this paper
• Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment

  2002cites this paper
• Immunohistochemically Detectable Bcl-2 Expression in Metastatic Melanoma: Association with Survival and Treatment Response

  2002cites this paper
• Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.

  2002cites this paper
• Targeting molecular mechanisms in cancer

  2002cites this paper
• Expression of CD40, CD44, bcl‐2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma

  2002cites this paper
• Expression of c-myc and bcl-2 in Primary and Advanced Cutaneous Melanoma

  2002cites this paper
• bcl-2 expression in head and neck cancer: an enigmatic prognostic marker.

  2001cites this paper
• p53 expression and apoptosis in melanomas of dogs and cats.

  2001cites this paper
• Drug‐resistance in human melanoma

  2001cites this paper
• Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

  2001cites this paper
• Antisense Downregulation of the Apoptosis-related Bcl-2 and Bcl-xL Proteins: A New Approach to Cancer Therapy

  2000cites this paper
• Update of diagnostic and prognostic markers in cutaneous malignant melanoma.

  2000cites this paper
• Proliferation, DNA ploidy, p53 overexpression and nuclear DNA fragmentation in six equine melanocytic tumours.

  2000cites this paper
• Cell cycle and melanoma – two different tumours from the same cell type

  2000cites this paper
• Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

  2000cites this paper
• Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

  2000cites this paper
• Heterogenous susceptibility to CD95‐induced apoptosis in melanoma cells correlates with bcl‐2 and bcl‐x expression and is sensitive to modulation by interferon‐γ

  1999cites this paper
• Ileocaecal Epstein–Barr virus‐positive lymphoproliferative disorder complicating Crohn's disease

  1999cites this paper
• c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma

  1999cites this paper
• Escaping cell death: survival proteins in cancer.

  1999cites this paper
• Coexistence of malignant melanoma, Hodgkin's disease and follicular lymphoma with expression of the B‐cell leukaemia/lymphoma (bcl‐2) oncogene

  1999cites this paper
• Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization.

  1999cites this paper
• Update of diagnostic and prognostic markers in cutaneous malignant melanoma.

  1999cites this paper
• MINIREVIEW Escaping Cell Death: Survival Proteins in Cancer

  1999cites this paper
• Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines

  1998cites this paper
• High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia.

  1998cites this paper
• Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells*

  1998cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis

  1998cites this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cites this paper
• Chemoresistance of Human Malignant Melanoma: Cellular and Molecular Aspects

  1998cites this paper
• CONTINUING MEDICAL EDUCATION

  1975cites this paper